network member

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

5323 Harry Hines Boulevard, Dallas TX 75390
Print

About Network Member

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty includes many distinguished members, including six who have been awarded Nobel Prizes since 1985. The faculty of almost 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. The Harold C. Simmons Comprehensive Cancer Center is the only NCI-designated Comprehensive Cancer Center in North Texas and one of just 48 NCI-designated Comprehensive Cancer Centers in the nation. Simmons Cancer Center includes 13 major cancer care programs with more than 250 adult and pediatric clinical trials open and enrolling at any given time. Simmons Cancer Center is among only 30 U.S. cancer research centers to be designated by the NCI as a National Clinical Trials Network Lead Academic Participating Site and is one of 15 sites included in the NCI Early Drug Development Opportunity Program (EDDOP). In addition, the Center’s education and training programs support and develop the next generation of cancer researchers and clinicians. Website: Harold C. Simmons Comprehensive Cancer Center
Erin Williams, Associate Director CRO Administration
Currently Enrolling

HCRN-GU23-626

Hispanic/Latino and non-Hispanic BlAck patients treated with niRaparib and abiraterone acetate plus prednisone for Metastatic hOrmone sensitive prostate cancer with deleterious homologous recombinatioN repair alterations: a phase II, open label studY (HARMONY)  
Cancer areas:Prostate
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Currently Enrolling

HCRN-GU21-517

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)
Cancer areas:Prostate
Moores Cancer Center at UC San Diego Health
The University of Chicago Medicine Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Currently Enrolling

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)
Cancer areas:Kidney
Beth Israel Deaconess Medical Center
Columbia University Irving Medical Center
Dana-Farber Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
John Theurer Cancer Center at Hackensack Meridian Health
Moores Cancer Center at UC San Diego Health
Penn Medicine Abramson Cancer Center
The Ohio State University
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Weill Cornell Medicine
Winship Cancer Institute of Emory University
Yale Cancer Center
Enrollment Closed

HCRN-GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma
Cancer areas:Kidney
Beth Israel Deaconess Medical Center
Cleveland Clinic Cancer Center
Columbia University Irving Medical Center
Fox Chase Cancer Center
Georgetown Lombardi Comprehensive Cancer Center
Penn Medicine Abramson Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Winship Cancer Institute of Emory University
Yale Cancer Center